<DOC>
	<DOCNO>NCT01191255</DOCNO>
	<brief_summary>This 58 week study compare ferric citrate active control 52 week ESRD dialysis patient , subsequently compare ferric citrate placebo 4 week .</brief_summary>
	<brief_title>A 58-Week Safety Efficacy Trial Ferric Citrate Patients With ESRD Dialysis</brief_title>
	<detailed_description>This trial three-period , multicenter , safety efficacy clinical trial . The first period two-week Washout Period , second period 52-week randomize , open-label , active control Safety Assessment Period , third period four-week , randomize , open-label , placebo-controlled Efficacy Assessment Period patient randomize treatment ferric citrate Safety Assessment Period . The primary objective trial determine long-term safety 52 week twelve ( 12 ) caplets/day KRX-0502 ( ferric citrate ) patient ESRD undergo either hemodialysis peritoneal dialysis determine efficacy KRX-0502 ( ferric citrate ) four-week , randomize , open-label , placebo-controlled Efficacy Assessment Period .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Males nonpregnant , nonbreastfeeding female 2 . Age ≥18 year 3 . On thriceweekly hemodialysis peritoneal dialysis least previous three month prior Screening 4 . Serum phosphorus ≥6.0 mg/dL study entry 5 . Taking less 318 pills/day current phosphate binder 6 . Willing discontinue current phosphate binder ( ) initiate ferric citrate 7 . Willing able give inform consent 8 . Life expectancy &gt; 1 year 1 . Parathyroidectomy within six month prior Screening 2 . Actively symptomatic gastrointestinal bleeding inflammatory bowel disease 3 . History multiple drug allergy intolerances 4 . History malignancy last five year ( treated cervical nonmelanomatous skin cancer may permit approve CCC ) 5 . Previous intolerance oral ferric citrate 6 . Intolerance oral ironcontaining product 7 . Psychiatric disorder interfere patient 's ability comply study protocol 8 . Inability tolerate oral drug intake 9 . Intolerance calcium acetate sevelamer carbonate 10 . Any medical condition render patient unable unlikely complete trial would interfere optimal participation trial produce significant risk patient 11 . Receipt investigational drug within 30 day Screening Visit ( Visit 0 ) 12 . Inability cooperate study personnel history noncompliance 13 . Unsuitable trial per Investigator 's clinical judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>ESRD</keyword>
	<keyword>end-stage renal disease</keyword>
	<keyword>dialysis</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>peritoneal dialysis</keyword>
	<keyword>hemodialysis ( HD )</keyword>
	<keyword>peritoneal dialysis ( PD )</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>phosphate binder</keyword>
	<keyword>kidney failure</keyword>
	<keyword>renal failure</keyword>
</DOC>